Caisse Des Depots ET Consignations Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Caisse Des Depots ET Consignations acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, HoldingsChannel reports. The fund acquired 20,438 shares of the medical equipment provider’s stock, valued at approximately $1,473,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. NEOS Investment Management LLC lifted its stake in Hologic by 28.5% in the fourth quarter. NEOS Investment Management LLC now owns 11,183 shares of the medical equipment provider’s stock valued at $806,000 after acquiring an additional 2,483 shares during the last quarter. UniSuper Management Pty Ltd raised its holdings in shares of Hologic by 22.9% in the 4th quarter. UniSuper Management Pty Ltd now owns 30,428 shares of the medical equipment provider’s stock valued at $2,194,000 after purchasing an additional 5,671 shares during the period. JPMorgan Chase & Co. lifted its stake in Hologic by 13.7% in the 4th quarter. JPMorgan Chase & Co. now owns 1,545,473 shares of the medical equipment provider’s stock valued at $111,413,000 after purchasing an additional 186,528 shares during the last quarter. Elo Mutual Pension Insurance Co grew its holdings in Hologic by 25.1% during the fourth quarter. Elo Mutual Pension Insurance Co now owns 25,888 shares of the medical equipment provider’s stock worth $1,866,000 after purchasing an additional 5,197 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Hologic by 3.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after buying an additional 129,035 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the subject of a number of recent analyst reports. Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective for the company. Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Stephens restated an “overweight” rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Finally, Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

NASDAQ:HOLX opened at $62.32 on Friday. The stock’s 50-day moving average is $65.41 and its 200-day moving average is $73.50. The stock has a market cap of $13.98 billion, a P/E ratio of 19.66, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.